1.97 USD
▲-0.01+2.07%
2026-08-03
市值
$265.09M
市盈率
—
EPS
-1.34
股息率
—
52 周区间
0.51 – 2.66
成交量
472.86K
Beta
0.43
目标价
4.60
52W 低 0.5152W 高 2.66
价格走势
公司简介
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of bre...